The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis
Open accessAbstract
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder that is characterized by amyloid β-protein deposition in senile plaques, neurofibrillary tangles consisting of abnormally phosphorylated tau protein, and neuronal loss leading to cognitive decline and dementia. Despite extensive research, the exact mechanisms underlying AD remain unknown and effective treatment is not available. Many hypotheses have been proposed to explain AD pathophysiology; however, there is general consensus that the abnormal aggregation of the amyloid β peptide (Aβ) is the initial event triggering a pathogenic cascade of degenerating events in cholinergic neurons. The dysregulation of calcium homeostasis has been studied considerably to clarify the mechanisms of neurodegeneration induced by Aβ. Intracellular calcium acts as a second messenger and plays a key role in the regulation of neuronal functions, such as neural growth and differentiation, action potential, and synaptic plasticity. The calcium hypothesis of AD posits that activation of the amyloidogenic pathway affects neuronal Ca2+ homeostasis and the mechanisms responsible for learning and memory. Aβ can disrupt Ca2+ signaling through several mechanisms, by increasing the influx of Ca2+ from the extracellular space and by activating its release from intracellular stores. Here, we review the different molecular mechanisms and receptors involved in calcium dysregulation in AD and possible therapeutic strategies for improving the treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
The versatility and universality of calcium signalling
Berridge, M. J., Lipp, P., & Bootman, M. D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036035 · Cited by 5,701
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Clapham, D. E. (2007) · Cell · doi:10.1016/j.cell.2007.11.028 · Cited by 4,175
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Close Contacts with the Endoplasmic Reticulum as Determinants of Mitochondrial Ca 2+ Responses
Rizzuto, R., Pinton, P., Carrington, W., Fay, F. S., Fogarty, K. E., Lifshitz, L. M., Tuft, R. A., & Pozzan, T. (1998) · Science · doi:10.1126/science.280.5370.1763 · Cited by 2,257
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
The molecular basis of CaMKII function in synaptic and behavioural memory
Lisman, J., Schulman, H., & Cline, H. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn753 · Cited by 1,860
Mitochondria as sensors and regulators of calcium signalling
Rizzuto, R., De Stefani, D., Raffaello, A., & Mammucari, C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3412 · Cited by 1,781
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Calcium and ROS: A mutual interplay
Görlach, A., Bertram, K., Hudecova, S., & Krizanova, O. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.010 · Cited by 1,546
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Chartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD).
Luscher, C., & Malenka, R. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005710 · Cited by 1,110
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., & Brinton, R. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903563106 · Cited by 940
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882
MAM: more than just a housekeeper
Hayashi, T., Rizzuto, R., Hajnoczky, G., & Su, T.-P. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.12.002 · Cited by 787
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
Protein transmission in neurodegenerative disease
Peng, C., Trojanowski, J. Q., & Lee, V. M.-Y. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0333-7 · Cited by 625
Kuchibhotla, K. V., Goldman, S. T., Lattarulo, C. R., Wu, H.-Y., Hyman, B. T., & Bacskai, B. J. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.008 · Cited by 614
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573
The Role of NMDA Receptors in Alzheimer’s Disease
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00043 · Cited by 535
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0238-6 · Cited by 450 · cited 2×
“This model is in agreement with those of α-synuclein in Parkinson’s disease and other neurodegenerative disorders [53,54].”
BackgroundResultThe Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442 · cited 1×
“Moreover, several studies demonstrated that Aβ oligomers have a key role in synaptic dysfunction and neuronal alterations [67–70], leading to cognitive impairment many years before the formation of amyloid plaques and neuronal death [71,72].”
BackgroundTau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo
Busche, M. A., Wegmann, S., Dujardin, S., Commins, C., Schiantarelli, J., Klickstein, N., Kamath, T. V., Carlson, G. A., Nelken, I., & Hyman, B. T. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0289-8 · Cited by 413
Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373
Takeda, S., Wegmann, S., Cho, H., DeVos, S. L., Commins, C., Roe, A. D., Nicholls, S. B., Carlson, G. A., Pitstick, R., Nobuhara, C. K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9490 · Cited by 371
Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicity
Friedrich, R. P., Tepper, K., Rönicke, R., Soom, M., Westermann, M., Reymann, K., Kaether, C., & Fändrich, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904532106 · Cited by 303 · cited 1×
“Several studies have suggested that the reuptake of extracellular Aβ into neurons may lead to neuronal damage and neurotoxicity [73].”
BackgroundGenetics of familial and sporadic Alzheimer s disease
Piaceri, I. (2013) · Frontiers in Bioscience · doi:10.2741/e605 · Cited by 256
Hong, S., Ostaszewski, B. L., Yang, T., O’Malley, T. T., Jin, M., Yanagisawa, K., Li, S., Bartels, T., & Selkoe, D. J. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.027 · Cited by 213
Mitochondrial alterations near amyloid plaques in an Alzheimer’s disease mouse model
Xie, H., Guan, J., Borrelli, L. A., Xu, J., Serrano-Pozo, A., & Bacskai, B. J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1836-13.2013 · Cited by 185
Braak, H., & Braak, E. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90032-9 · Cited by 181
Dourlen, P., Kilinc, D., Malmanche, N., Chapuis, J., & Lambert, J.-C. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02004-0 · Cited by 168
Mark, R. J., Keller, J. N., Kruman, I., & Mattson, M. P. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00196-0 · Cited by 167
He, N., Jin, W.-L., Lok, K.-H., Wang, Y., Yin, M., & Wang, Z.-J. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.437 · Cited by 151
Tau accumulation triggers STAT1‐dependent memory deficits by suppressing NMDA receptor expression
Li, X., Hong, X., Wang, Y., Zhang, S., Zhang, J., Li, X., Liu, Y., Sun, D., Feng, Q., Ye, J., et al. (2019) · The EMBO Reports · doi:10.15252/embr.201847202 · Cited by 81
Molecular mechanism of intramembrane proteolysis by γ-secretase
Tomita, T. (2014) · The Journal of Biochemistry · doi:10.1093/jb/mvu049 · Cited by 58
Research works printed but not linked: 173
- Brookmeyer, 2007, Forecasting the global burden of Alzheimer’s disease, Alzheimers Dement., 3, 186, 10.1016/j.jalz.2007.04.381 · DOI · Paper page
- Elahi, 2017, A clinicopathological approach to the diagnosis of dementia, Nat. Rev. Neurol., 13, 457, 10.1038/nrneurol.2017.96 · DOI · Paper page
- Cacabelos, 2007, Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics, Neuropsychiatr. Dis. Treat., 3, 303
- Olin, J.T., and Schneider, L. (2002). Galantamine for Alzheimer’s disease. Cochrane Database Syst. Rev. · DOI
- Hampel, 2019, Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease, Dialogues Clin. Neurosci., 21, 177, 10.31887/DCNS.2019.21.2/hhampel · DOI
- Iqbal, 1984, Alzheimer paired helical filaments: Immunochemical identification of polypeptides, Acta Neuropathol., 62, 259, 10.1007/BF00687607 · DOI
- Steinman, 2021, Microvascular alterations in Alzheimer’s disease, Front. Cell. Neurosci., 14, 618986, 10.3389/fncel.2020.618986 · DOI
- Olsson, 2016, CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis, Lancet Neurol., 15, 673, 10.1016/S1474-4422(16)00070-3 · DOI · Paper page
- Lista, 2017, Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease, Expert Rev. Neurother., 17, 47, 10.1080/14737175.2016.1204234 · DOI
- Baldacci, 2017, Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases, Expert Rev. Proteom., 14, 285, 10.1080/14789450.2017.1304217 · DOI · Paper page
- Tong, 2014, Brain metabolic dysfunction at the core of Alzheimer’s disease, Biochem. Pharmacol., 88, 548, 10.1016/j.bcp.2013.12.012 · DOI · Paper page
- Hardy, 2002, The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
- Watts, 2017, β-Amyloid Prions and the Pathobiology of Alzheimer’s Disease, Cold Spring Harb. Perspect. Biol., 8, a023507, 10.1101/cshperspect.a023507 · DOI
- Barber, R.C. (2012). The Genetics of Alzheimer’s Disease. Scientifica, 246210. · DOI
- Liu, 2019, Enriched gestation activates the IGF pathway to evoke embryo-adult benefits to prevent Alzheimer’s disease, Transl. Neurodegener., 8, 8, 10.1186/s40035-019-0149-9 · DOI
- Lambert, 2011, Genetics of Alzheimer’s disease: New evidences for an old hypothesis?, Curr. Opin. Genet. Dev., 21, 295, 10.1016/j.gde.2011.02.002 · DOI
- Guo, 2019, Elevation of pS262-tau and Demethylated PP2A in retina occurs earlier than in Hippocampus during Hyperhomocysteinemia, J. Alzheimers Dis., 68, 367, 10.3233/JAD-180978 · DOI
- Xu, 2016, Biomarkers for early diagnostic of mild cognitive impairment in Type-2 diabetes patients: A multicentre, retrospective, Nested Case-Control Study, EBioMedicine, 5, 105, 10.1016/j.ebiom.2016.02.014 · DOI
- Zhang, 2019, Liraglutide ameliorates hyperhomocysteinemia-induced Alzheimer-like pathology and memory deficits in rats via multi-molecular targeting, Neurosci. Bull., 35, 724, 10.1007/s12264-018-00336-7 · DOI
- Thinakaran, 2008, Amyloid precursor protein trafficking, processing, and function, J. Biol. Chem., 283, 29615, 10.1074/jbc.R800019200 · DOI · Paper page
- Li, 2000, Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1, Nature, 405, 689, 10.1038/35015085 · DOI · Paper page
- Duff, 1996, Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1, Nature, 383, 710, 10.1038/383710a0 · DOI · Paper page
- Borchelt, 1996, Familial Alzheimer’s disease-linked presenilin 1 variants elevate Aβ1–42/1–40 ratio in vitro and in vivo, Neuron, 17, 1005, 10.1016/S0896-6273(00)80230-5 · DOI · Paper page
- Kanatsu, 2014, Decreased CALM expression reduces Aβ42 to total Aβ ratio through clathrin-mediated endocytosis of γ-secretase, Nat. Commun., 5, 3386, 10.1038/ncomms4386 · DOI
- Bitan, 2003, Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways, Proc. Natl. Acad. Sci. USA, 100, 330, 10.1073/pnas.222681699 · DOI · Paper page
- Roychaudhuri, 2009, Amyloid β-Protein Assembly and Alzheimer Disease, J. Biol. Chem., 284, 4749, 10.1074/jbc.R800036200 · DOI · Paper page
- Gao, 2018, Tau in Alzheimer’s disease: Mechanisms and therapeutic strategies, Curr. Alzheimer Res., 15, 283, 10.2174/1567205014666170417111859 · DOI · Paper page
- Guo, 2017, Roles of tau protein in health and disease, Acta Neuropathol., 133, 665, 10.1007/s00401-017-1707-9 · DOI · Paper page
- Alonso, 2001, Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments, Proc. Natl. Acad. Sci. USA, 98, 6923, 10.1073/pnas.121119298 · DOI · Paper page
- Iqbal, 2010, Tau in Alzheimer disease and related tauopathies, Curr. Alzheimer Res., 7, 656, 10.2174/156720510793611592 · DOI · Paper page
- Sowade, 2017, Seed-induced acceleration of amyloid-betamediated neurotoxicity in vivo, Nat. Commun., 8, 512, 10.1038/s41467-017-00579-4 · DOI
- Hardy, 2006, Has the amyloid cascade hypothesis for Alzheimer’s disease been proved?, Curr. Alzheimer Res., 3, 71, 10.2174/156720506775697098 · DOI · Paper page
- Buccafusco, J.J. (2009). Transgenic mouse models of Alzheimer’s disease: Behavioral testing and considerations. Methods of Behavior Analysis in Neuroscience, CRC Press. [2nd ed.].
- Walsh, 2004, Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration, Protein Pept. Lett., 11, 213, 10.2174/0929866043407174 · DOI · Paper page
- Selkoe, 2008, Biochemistry and molecular biology of amyloid β-protein and the mechanism of Alzheimer’s disease, Handb. Clin. Neurol., 89, 245, 10.1016/S0072-9752(07)01223-7 · DOI · Paper page
- Irvine, 2008, Protein aggregation in the brain: The molecular basis for Alzheimer’s and Parkinson’s diseases, Mol. Med., 14, 451, 10.2119/2007-00100.Irvine · DOI · Paper page
- Busche, 2012, Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease, Proc. Natl. Acad. Sci. USA, 109, 8740, 10.1073/pnas.1206171109 · DOI · Paper page
- Hudry, 2017, Soluble oligomeric amyloid-β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain, Mol. Neurodegener., 12, 27, 10.1186/s13024-017-0169-9 · DOI · Paper page
- Ferreira, 2015, Aβ and NMDAR activation cause mitochondrial dysfunction involving ER calcium release, Neurobiol. Aging, 36, 680, 10.1016/j.neurobiolaging.2014.09.006 · DOI
- Kayed, 2013, Molecular Mechanism of amyloid Oligomers Toxicity, J. Alzheimers Dis., 33, S67, 10.3233/JAD-2012-129001 · DOI · Paper page
- Cecchi, 2013, The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity, Biophys. Chem., 182, 30, 10.1016/j.bpc.2013.06.003 · DOI
- Zampagni, 2010, Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane, J. Mol. Med., 88, 597, 10.1007/s00109-010-0603-8 · DOI
- Evangelisti, 2016, Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases, Sci. Rep., 6, 32721, 10.1038/srep32721 · DOI
- Bigi, 2020, Targeting pathological amyloid aggregates with conformation-sensitive antibodies, Curr. Alzheimer Res., 17, 722, 10.2174/1567205017666201109093848 · DOI
- Cecchi, 1999, Glutathione level is altered in lymphoblasts from patients with familial Alzheimer’s disease, Neurosci. Lett., 275, 152, 10.1016/S0304-3940(99)00751-X · DOI · Paper page
- Pensalfini, 2008, Protective effect of new S-acylglutathione derivatives against amyloid-induced oxidative stress, Free Rad. Biol. Med., 44, 1624, 10.1016/j.freeradbiomed.2008.01.025 · DOI
- Pensalfini, 2011, Membrane cholesterol enrichment prevents Aβ-induced oxidative stress in Alzheimer’s fibroblasts, Neurobiol. Aging, 32, 210, 10.1016/j.neurobiolaging.2009.02.010 · DOI
- Cenini, 2010, Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways, Amino Acids, 38, 1101, 10.1007/s00726-009-0339-3 · DOI
- Zampagni, 2012, Novel S-acyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models, Free Radic. Biol. Med., 52, 1362, 10.1016/j.freeradbiomed.2012.01.012 · DOI
- Cascella, 2014, S-linolenoyl glutathione intake extends life-span and stress resistance via Sir-2.1 upregulation in Caenorhabditis elegans, Free Radic. Biol. Med., 73, 127, 10.1016/j.freeradbiomed.2014.05.004 · DOI
- Jackson, 2016, Cellular proteostasis: Degradation of misfolded proteins by lysosomes, Essay Biochem., 60, 173, 10.1042/EBC20160005 · DOI
- Höhn, A., Tramutola, A., and Cascella, R. (2020). Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress. Oxid. Med. Cell. Longev., 5497046. · DOI · Paper page
- Salminen, 2013, Impaired autophagy and APP processing in Alzheimer’s disease: The potential role of Beclin 1 interactome, Prog. Neurobiol., 106–107, 33, 10.1016/j.pneurobio.2013.06.002 · DOI · Paper page
- Lobello, 2012, Targeting Beta amyloid: A clinical review of immunotherapeutic approaches in Alzheimer’s disease, Int. J. Alzheimers Dis., 2012, 628070
- Cascella, 2013, Extracellular chaperones prevent Aβ42-induced toxicity in rat brains, Biochim. Biophys. Acta, 1832, 1217, 10.1016/j.bbadis.2013.04.012 · DOI
- Bennett, 2017, Enhanced tau aggregation in the presence of amyloid β, Am. J. Pathol., 187, 1601, 10.1016/j.ajpath.2017.03.011 · DOI · Paper page
- Hanseeuw, 2019, Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study, JAMA Neurol., 76, 915, 10.1001/jamaneurol.2019.1424 · DOI · Paper page
- Timmers, 2019, Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer’s disease, Neurobiol. Aging, 79, 131, 10.1016/j.neurobiolaging.2019.03.016 · DOI
- Majdi, 2020, Amyloid- β, tau, and the cholinergic system in Alzheimer’s disease: Seeking direction in a tangle of clues, Rev. Neurosci., 31, 391, 10.1515/revneuro-2019-0089 · DOI
- Lynch, 1989, Links between long-term potentiation and neuropathology. An hypothesis involving calcium-activated proteases, Ann. N. Y. Acad. Sci., 568, 171, 10.1111/j.1749-6632.1989.tb12505.x · DOI
- Briggs, 2017, Emerging pathways driving early synaptic pathology in Alzheimer’s disease, Biochem. Biophys. Res. Commun., 19, 988, 10.1016/j.bbrc.2016.09.088 · DOI
- Pchitskaya, 2018, Calcium signaling and molecular mechanisms underlying neurodegenerative diseases, Cell Calcium, 70, 87, 10.1016/j.ceca.2017.06.008 · DOI · Paper page
- Zampese, 2012, Intracellular organelles in the saga of Ca2+ homeostasis: Different molecules for dierent purposes?, Cell. Mol. Life Sci., 69, 1077, 10.1007/s00018-011-0845-9 · DOI
- Supnet, 2010, The dysregulation of intracellular calcium in Alzheimer disease, Cell Calcium, 47, 183, 10.1016/j.ceca.2009.12.014 · DOI · Paper page
- LaFerla, 2002, Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease, Nat. Rev. Neurosci., 3, 862, 10.1038/nrn960 · DOI · Paper page
- Green, 2008, Linking calcium to Abeta and Alzheimer’s disease, Neuron, 59, 190, 10.1016/j.neuron.2008.07.013 · DOI · Paper page
- Mark, 1995, Amyloid beta-peptide impairs ion-motive ATPase activities: Evidence for a role in loss of neuronal Ca2+ homeostasis and cell death, J. Neurosci., 15, 6239, 10.1523/JNEUROSCI.15-09-06239.1995 · DOI · Paper page
- Santos, 2010, Network excitability dysfunction in Alzheimer’s disease: Insights from in vitro and in vivo models, Rev. Neurosci., 21, 153
- Berridge, 1998, Neuronal calcium signaling, Neuron, 2, 13, 10.1016/S0896-6273(00)80510-3 · DOI · Paper page
- Kang, 2001, An important role of neural activity-dependent CaMKIV signaling in the consolidation of long-term memory, Cell, 106, 771, 10.1016/S0092-8674(01)00497-4 · DOI · Paper page
- Burgoyne, 2019, Calcium sensors in neuronal function and dysfunction, Cold Spring Harb. Perspect. Biol., 11, a035154, 10.1101/cshperspect.a035154 · DOI
- Wang, 2017, Calcium Dysregulation in Alzheimer’s Disease: A Target for New Drug Development, J. Alzheimers Dis. Parkinsonism, 7, 374, 10.4172/2161-0460.1000374 · DOI
- Prole, 2019, Structure and function of ip3 receptors, Cold Spring Harb. Perspect. Biol., 11, a035063, 10.1101/cshperspect.a035063 · DOI · Paper page
- Santulli, 2017, Intracellular calcium release channels: An update, J. Physiol., 595, 3041, 10.1113/JP272781 · DOI · Paper page
- Krebs, 2015, Ca2+ homeostasis and endoplasmic reticulum (ER) stress: An integrated view of calcium signaling, Biochem. Biophys. Res. Commun., 460, 114, 10.1016/j.bbrc.2015.02.004 · DOI · Paper page
- Putney, 2017, The functions of store-operated calcium channels, Biochim. Biophys. Acta Mol. Cell Res., 1864, 900, 10.1016/j.bbamcr.2016.11.028 · DOI
- Prakriya, 2015, Store-operated calcium channels, Physiol. Rev., 95, 1383, 10.1152/physrev.00020.2014 · DOI · Paper page
- Staord, 2017, The plasma membrane calcium ATPases and their role as major new players in human disease, Physiol. Rev., 97, 1089, 10.1152/physrev.00028.2016 · DOI
- DiPolo, 2006, Sodium/calcium exchanger: Influence of metabolic regulation on ion carrier interactions, Physiol. Rev., 86, 155, 10.1152/physrev.00018.2005 · DOI · Paper page
- Baughman, 2011, Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter, Nature, 476, 341, 10.1038/nature10234 · DOI · Paper page
- Raffaello, 2011, A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter, Nature, 476, 336, 10.1038/nature10230 · DOI · Paper page
- Palty, 2010, NCLX is an essential component of mitochondrial Na+/Ca2+ exchange, Proc. Natl. Acad. Sci. USA, 107, 436, 10.1073/pnas.0908099107 · DOI · Paper page
- Jiang, 2009, Genome-wide RNAi screen identifies Letm1 as a mitochondrial Ca2+/H+ antiporter, Science, 326, 144, 10.1126/science.1175145 · DOI · Paper page
- Bronner, 2001, Extracellular and intracellular regulation of calcium homeostasis, Sci. World J., 1, 919, 10.1100/tsw.2001.489 · DOI
- Vance, 2014, MAM (mitochondria-associated membranes) in mammalian cells: Lipids and beyond, Biochim. Biophys. Acta, 1841, 4
- Hayashi, 2010, Cholesterol at the endoplasmic reticulum: Roles of the sigma-1 receptor chaperone and implications thereof in human diseases, Subcell. Biochem., 51, 381, 10.1007/978-90-481-8622-8_13 · DOI
- Pinton, 2018, Mitochondria-associated membranes (MAMs) and pathologies editorial, Cell Death Dis., 9, 413, 10.1038/s41419-018-0424-1 · DOI
- Khachaturian, 1989, Calcium, membranes, aging, and Alzheimer’s disease. Introduction and overview, Ann. N. Y. Acad. Sci., 568, 1, 10.1111/j.1749-6632.1989.tb12485.x · DOI · Paper page
- Landfield, 1984, Prolonged Ca2+-dependent after hyperpolarizations in hippocampal neurons of aged rats, Science, 226, 1, 10.1126/science.6494926 · DOI · Paper page
- Landfield, 1987, Increased calcium current’ hypothesis of brain aging, Neurobiol. Aging, 8, 346, 10.1016/0197-4580(87)90074-1 · DOI · Paper page
- Verkhratsky, 1998, Calcium and neuronal ageing, Trends Neurosci., 21, 2, 10.1016/S0166-2236(97)01156-9 · DOI · Paper page
- Toescu, 2004, Ca2+ regulation and gene expression in normal brain aging, Trends Neurosci., 27, 614, 10.1016/j.tins.2004.07.010 · DOI · Paper page
- Toescu, 2007, The importance of being subtle: Small changes in calcium homeostasis control cognitive decline in normal aging, Aging Cell, 6, 267, 10.1111/j.1474-9726.2007.00296.x · DOI · Paper page
- Foster, 2007, Calcium homeostasis and modulation of synaptic plasticity in the aged brain, Aging Cell, 6, 319, 10.1111/j.1474-9726.2007.00283.x · DOI · Paper page
- Bezprozvanny, 2009, Calcium signaling and neurodegenerative diseases, Trends Mol. Med., 15, 89, 10.1016/j.molmed.2009.01.001 · DOI · Paper page
- Querfurth, 1994, Calcium ionophore increases amyloid β peptide production by cultured cells, Biochemistry, 33, 4550, 10.1021/bi00181a016 · DOI · Paper page
- Bezprozvanny, 2008, Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease, Trends Neurosci., 31, 454, 10.1016/j.tins.2008.06.005 · DOI · Paper page
- Etcheberrigaray, 1998, Calcium responses in fibroblasts from asymptomatic members of Alzheimer’s disease families, Neurobiol. Dis., 5, 37, 10.1006/nbdi.1998.0176 · DOI
- Latulippe, J., and Lotito, D. (2018). A mathematical model for the effects of amyloid beta on intracellular calcium. PLoS ONE, 13. · DOI
- Demuro, 2005, Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers, J. Biol. Chem., 280, 17294, 10.1074/jbc.M500997200 · DOI · Paper page
- Evangelisti, 2012, Membrane lipid composition and its physicochemical properties define cell vulnerability to aberrant protein oligomers, J. Cell Sci., 125, 2416
- Limbocker, 2019, Trodusquemine enhances Aβ42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes, Nat. Commun., 10, 225, 10.1038/s41467-018-07699-5 · DOI
- Limbocker, 2020, Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism, Commun. Biol., 3, 435, 10.1038/s42003-020-01140-8 · DOI
- Evangelisti, 2013, Lipid rafts mediate amyloid-induced calcium dyshomeostasis and oxidative stress in Alzheimer’s disease, Curr. Alzheimer Res., 10, 143, 10.2174/1567205011310020004 · DOI
- Ladiwala, 2012, Conformational differences between two amyloid beta oligomers of similar size and dissimilar toxicity, J. Biol. Chem., 287, 24765, 10.1074/jbc.M111.329763 · DOI · Paper page
- Contrusciere, 2010, Lipid raft disruption protects mature neurons against amyloid oligomer toxicity, Biochim. Biophys. Acta, 1802, 406, 10.1016/j.bbadis.2010.01.007 · DOI
- Cascella, 2017, Soluble oligomers require a ganglioside to trigger neuronal calcium overload, J. Alzheimers Dis., 60, 923, 10.3233/JAD-170340 · DOI
- Schengrund, 2010, Lipid rafts: Keys to neurodegeneration, Brain Res. Bull., 82, 7, 10.1016/j.brainresbull.2010.02.013 · DOI
- Gunther, 2012, Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons, Nat. Neurosci., 15, 1227, 10.1038/nn.3178 · DOI · Paper page
- Calamai, 2016, Single molecule experiments emphasize GM1 as a key player of the different cytotoxicity of structurally distinct Aβ1-42 oligomers, Biochim. Biophys. Acta, 1858, 386, 10.1016/j.bbamem.2015.12.009 · DOI
- Fonseca, 2015, Amyloid-beta disrupts calcium and redox homeostasis in brain endothelial cells, Mol. Neurobiol., 51, 610, 10.1007/s12035-014-8740-7 · DOI
- Ranjan, B., Chong, K.H., and Zheng, J. (2018). Composite mathematical modeling of calcium signaling behind neuronal cell death in Alzheimer’s disease. BMC Syst. Biol., 12. · DOI
- Yang, 2009, Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity, J. Neurosci., 29, 15660, 10.1523/JNEUROSCI.4104-09.2009 · DOI
- Arispe, 1993, Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum, Proc. Natl. Acad. Sci. USA, 90, 567, 10.1073/pnas.90.2.567 · DOI · Paper page
- Bhatia, 2000, Fresh and globular amyloid beta protein (1–42) induces rapid cellular degeneration: Evidence for Abeta P channel-mediated cellular toxicity, FASEB J., 14, 1233, 10.1096/fasebj.14.9.1233 · DOI · Paper page
- Kagan, 2002, The channel hypothesis of Alzheimer’s disease: Current status, Peptides, 23, 1311, 10.1016/S0196-9781(02)00067-0 · DOI · Paper page
- Arispe, 2007, Abeta ion channels. Prospects for treating Alzheimer’s disease with Abeta channel blockers, Biochim. Biophys. Acta, 1768, 1952, 10.1016/j.bbamem.2007.03.014 · DOI · Paper page
- Sokolov, 2006, Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure, J. Gen. Physiol., 128, 637, 10.1085/jgp.200609533 · DOI · Paper page
- Samad, 2017, Calcium Regulation in Alzheimer’s Disease: Mechanistic Understanding, J. Coll. Physicians Surg. Pak., 27, 566
- Reese, 2011, A role for calcineurin in Alzheimer’s disease, Curr. Neuropharmacol., 9, 685, 10.2174/157015911798376316 · DOI
- Yin, 2016, Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling, Proc. Natl. Acad. Sci. USA, 113, E3773, 10.1073/pnas.1604519113 · DOI · Paper page
- Cavallucci, 2013, Calcineurin inhibition rescues early synaptic plasticity deficits in a mouse model of Alzheimer’s disease, NeuroMol. Med., 15, 541, 10.1007/s12017-013-8241-2 · DOI
- Lin, 2018, Endoplasmic reticulum stress induces spatial memory deficits by activating GSK-3, J. Cell. Mol. Med., 22, 3489, 10.1111/jcmm.13626 · DOI
- Liu, 2016, SIL1 rescued bip elevation-related tau hyperphosphorylation in ER stress, Mol. Neurobiol., 53, 983, 10.1007/s12035-014-9039-4 · DOI
- Zhang, 2021, δ-Secretase-cleaved Tau stimulates Aβ production via upregulating STAT1-BACE1 signaling in Alzheimer’s disease, Mol. Psychiatry, 26, 586, 10.1038/s41380-018-0286-z · DOI
- Galla, L., Redolfi, N., Pozzan, T., Pizzo, P., and Greotti, E. (2020). Intracellular calcium dysregulation by the Alzheimer’s disease-linked protein presenilin 2. Int. J. Mol. Sci., 21. · DOI
- Gaspar, 1994, Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice, Neuroscience, 61, 293, 10.1016/0306-4522(94)90232-1 · DOI
- Damier, 1999, The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease, Brain, 122, 1437, 10.1093/brain/122.8.1437 · DOI · Paper page
- Foehring, 2009, Endogenous calcium buffering capacity of substantia nigral dopamine neurons, J. Neurophysiol., 102, 2326, 10.1152/jn.00038.2009 · DOI
- Lombardo, 2015, Role of the nicotinic acetylcholine receptor in Alzheimer’s disease pathology and treatment, Neuropharmacology, 96, 255, 10.1016/j.neuropharm.2014.11.018 · DOI · Paper page
- Hermann, 2013, Synthetic Aβ oligomers (Aβ1-42 globulomer) modulate presynaptic calcium currents: Prevention of Aβ-induced synaptic deficits by calcium channel blockers, Eur. J. Pharmacol., 702, 44, 10.1016/j.ejphar.2013.01.030 · DOI
- Ueda, 1997, Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: A possible involvement of free radicals, J. Neurochem., 68, 265, 10.1046/j.1471-4159.1997.68010265.x · DOI · Paper page
- Willis, 2010, L-type calcium channel CaV 1.2 in transgenic mice overexpressing human AbetaPP751 with the London (V717I) and Swedish (K670M/N671L) mutations, J. Alzheimers Dis., 20, 1167, 10.3233/JAD-2010-091117 · DOI
- Kim, 2011, Effects of amyloid-β peptides on voltage-gated L-type Ca(V)1.2 and Ca(V)1.3 Ca(2+) channels, Mol. Cells, 32, 289, 10.1007/s10059-011-0075-x · DOI
- Kelly, 2006, Beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons, J. Biol. Chem., 281, 28079, 10.1074/jbc.M605081200 · DOI · Paper page
- Beitz, 1997, The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes, Brain Res., 754, 65, 10.1016/S0006-8993(97)00043-7 · DOI
- Brera, 2004, Beta-amyloid25–35 inhibits glutamate uptake in cultured neurons and astrocytes: Modulation of uptake as a survival mechanism, Neurobiol. Dis., 15, 580, 10.1016/j.nbd.2003.12.006 · DOI
- Kervern, 2012, Selective impairment of some forms of synaptic plasticity by oligomeric amyloid-β peptide in the mouse hippocampus: Implication of extrasynaptic NMDA receptors, J. Alzheimers Dis., 32, 183, 10.3233/JAD-2012-120394 · DOI
- Fani, 2021, Aβ Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors, ACS Chem. Neurosci., 12, 766, 10.1021/acschemneuro.0c00811 · DOI
- Ferreira, 2012, Amyloid beta peptide 1–42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures, Cell Calcium, 51, 95, 10.1016/j.ceca.2011.11.008 · DOI · Paper page
- Costa, 2012, Amyloid β-induced ER stress is enhanced under mitochondrial dysfunction conditions, Neurobiol. Aging, 33, 824.e5, 10.1016/j.neurobiolaging.2011.04.011 · DOI
- Ferreira, 2015, Soluble amyloid-βoligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease, Front. Cell. Neurosci., 26, 191
- Nomura, 2005, Mechanism of impairment of long-term potentiation by amyloid β is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons, Neurosci. Lett., 391, 1, 10.1016/j.neulet.2005.08.024 · DOI
- Liu, 2012, Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells, Nat. Cell Biol., 14, 177, 10.1038/ncb2422 · DOI · Paper page
- Bezprozvanny, 2013, The synaptic maintenance problem: Membrane recycling, Ca2+ homeostasis and late onset degeneration, Mol. Neurodegener., 8, 23, 10.1186/1750-1326-8-23 · DOI
- Francis, 2008, Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer’s disease, Neurodegener. Dis., 5, 241, 10.1159/000113713 · DOI
- Mota, 2012, Amyloid-beta peptide1–42 causes microtubule deregulation through N-methyl-D-aspartate receptors in mature hippocampal cultures, Curr. Alzheimer Res., 9, 844, 10.2174/156720512802455322 · DOI
- Paschen, 2003, Endoplasmic reticulum: A primary target in various acute disorders and degenerative diseases of the brain, Cell Calcium, 34, 365, 10.1016/S0143-4160(03)00139-8 · DOI · Paper page
- Verkhratsky, 2002, The endoplasmic reticulum and neuronal calcium signaling, Cell Calcium, 32, 393, 10.1016/S0143416002001896 · DOI · Paper page
- Chakroborty, 2009, Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic3xTg-AD mice, J. Neurosci., 29, 9458, 10.1523/JNEUROSCI.2047-09.2009 · DOI · Paper page
- Ferreiro, 2004, Involvement of endoplasmic reticulum Ca2+ release through ryanodine and inositol 1,4,5-triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide, J. Neurosci. Res., 76, 872, 10.1002/jnr.20135 · DOI
- Ferreiro, 2006, An endoplasmicreticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity, Neurobiol. Dis., 23, 669, 10.1016/j.nbd.2006.05.011 · DOI · Paper page
- Supnet, 2006, Amyloid-beta-(1–42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice, J. Biol. Chem., 281, 38440, 10.1074/jbc.M606736200 · DOI
- Adasme, 2011, Amyloid β-peptide oligomers stimulate RyR-mediated Ca2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent RyR-mediated dendritic spine remodeling produced by BDNF, Antioxid. Redox Signal., 14, 1209, 10.1089/ars.2010.3287 · DOI
- Wang, 2019, Ca(2+) homeostasis dysregulation in Alzheimer’s disease: A focus on plasma membrane and cell organelles, FASEB J., 33, 6697, 10.1096/fj.201801751R · DOI
- Kelly, 1996, Amyloid beta-peptide disrupts carbachol induced muscarinic cholinergic signal transduction in control neurons, Proc. Natl. Acad. Sci. USA, 93, 6753, 10.1073/pnas.93.13.6753 · DOI · Paper page
- Paschen, 2001, Dependence of vital cell function on endoplasmic reticulum calcium levels: Implications for the mechanisms underlying neuronal cell injury in different pathological states, Cell Calcium, 29, 1, 10.1054/ceca.2000.0162 · DOI
- Pannaccione, 2012, A new concept: Aβ1-42 generates a Hyperfunctional proteolytic NCX3 fragment that delays caspase-12 activation and neuronal death, J. Neurosci., 32, 10609, 10.1523/JNEUROSCI.6429-11.2012 · DOI
- Ito, 1994, Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease, Proc. Natl. Acad. Sci. USA, 91, 534, 10.1073/pnas.91.2.534 · DOI · Paper page
- Hirashima, 1996, Calcium responses in human fibroblasts: A diagnostic molecular profile for Alzheimer’s disease, Neurobiol. Aging, 17, 549, 10.1016/0197-4580(96)00074-7 · doi:10.1016/0197-4580(96)00074-7
- Goldstein, 2000, The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant, Nat. Cell Biol., 2, 156, 10.1038/35004029 · DOI · Paper page
- Atamna, 2007, 2nd Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease, Mitochondrion, 7, 297, 10.1016/j.mito.2007.06.001 · DOI · Paper page
- Santos, 2010, A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer’s disease, J. Alzheimers Dis., 20, S401, 10.3233/JAD-2010-100666 · DOI · Paper page
- Kopeikina, 2011, Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer’s disease brain, Am. J. Pathol., 179, 2071, 10.1016/j.ajpath.2011.07.004 · DOI · Paper page
- Brown, 2006, Synaptic mitochondria are more susceptible to Ca2+ overload than nonsynaptic mitochondria, J. Biol. Chem., 281, 11658, 10.1074/jbc.M510303200 · DOI · Paper page
- Zervas, 2005, Impaired hippocampal long-term potentiation in microtubule-associated protein 1B-deficient mice, J. Neurosci. Res., 82, 83, 10.1002/jnr.20624 · DOI
- Fukunaga, 1996, CaM kinase II in long-term potentiation, Neurochem. Int., 28, 343, 10.1016/0197-0186(95)00097-6 · DOI
- Sanz-Blasco, S., Valero, R.A., Rodriguez-Crespo, I., Villalobos, C., and Nunez, L. (2008). Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE, 3. · DOI · Paper page
- Villalobos, 2016, Aging enables Ca2+ overload and apoptosis induced by amyloid-beta oligomers in rat hippocampal neurons: Neuroprotection by non-steroidal anti-inflammatory drugs and R-flurbiprofen in aging neurons, J. Alzheimers Dis., 54, 207, 10.3233/JAD-151189 · DOI
- Ferreiro, 2008, The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial apoptotic pathway, Neurobiol. Dis., 30, 331, 10.1016/j.nbd.2008.02.003 · DOI · Paper page
- Hou, 2020, Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer’s disease, Nat. Commun., 11, 2146, 10.1038/s41467-020-16074-2 · DOI · Paper page
- Supnet, 2010, Neuronal calcium signaling, mitochondrial dysfunction and Alzheimer’s disease, J. Alzheimers Dis., 20, S487, 10.3233/JAD-2010-100306 · DOI · Paper page
- Bonilla, 2018, A key role for MAM in mediating mitochondrial dysfunction in alzheimer disease, Cell Death Dis., 9, 335, 10.1038/s41419-017-0215-0 · DOI · Paper page
Cited by
Di Benedetto, G., Burgaletto, C., Bellanca, C. M., Munafò, A., Bernardini, R., & Cantarella, G. (2022) · Cells · doi:10.3390/cells11172728 · Cited by 189
Anderson, A. G., Rogers, B. B., Loupe, J. M., Rodriguez-Nunez, I., Roberts, S. C., White, L. M., Brazell, J. N., Bunney, W. E., Bunney, B. G., Watson, S. J., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100263 · Cited by 82
“In AD neurons, we found decreased expression of ryanodine receptor 3 (RYR3) and inositol 1,4,5-trisphosphate receptor type 2 (ITPR2) that both release internal stores of Ca from the endoplasmic reticulum.(78)We alsomeasured decreased expression of the Ca sensors calmodulin (CALM1,CALM2,CALM3) and VILIP-1 (VSNL1), the…”
BackgroundThe Role of Oxygen Homeostasis and the HIF-1 Factor in the Development of Neurodegeneration
Mitroshina, E. V., & Vedunova, M. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094581 · Cited by 48
Cerasuolo, M., Di Meo, I., Auriemma, M. C., Paolisso, G., Papa, M., & Rizzo, M. R. (2024) · Biomolecules · doi:10.3390/biom14111362 · Cited by 47
Modulation of microRNAs through Lifestyle Changes in Alzheimer’s Disease
Pinto-Hernandez, P., Castilla-Silgado, J., Coto-Vilcapoma, A., Fernández-Sanjurjo, M., Fernández-García, B., Tomás-Zapico, C., & Iglesias-Gutiérrez, E. (2023) · Nutrients · doi:10.3390/nu15173688 · Cited by 22
Metadata
- Authors
- Cascella, R., & Cecchi, C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-05-06
- Volume
- 22
- Issue
- 9
- Pages
- 4914
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3158914992
- Cited by
- 185
- References
- 57
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.